Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmond is slated for broadcast at 7 p.m. ET on June 11. During the interview, which is hosted by RedChip CEO Dave Gentry, Redmond discusses the company, including the development of its novel compound, which could be the first FDA-approved treatment for concussions. With more than 5 million concussions reported in the United States each year and an estimated 69 million occurring worldwide, the potential in the $400 billion market is significant. In addition, Redmond provides an overview of ODYY’s medical products pipeline, including CardioMap(R), a monitoring and screening device for early detection of coronary artery disease, and Save-A-Life(R), a handheld choking rescue device for consumer use. The RedChip Money Report is produced by RedChip Companies Inc., an international investor relations and media firm with some three decades of experience. The RedChip Money Report delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
To view the full interview, visit https://ibn.fm/OHz5T
To view the full press release, visit https://ibn.fm/PdhiG
About Odyssey Health Inc.
Odyssey Health Inc., formerly Odyssey Group International, is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork